US Patent

US8486947 — Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands

Method of Use · Assigned to Bioprojet SC · Expires 2029-09-26 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a new method of treatment for Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, and vascular dementia using non-imidazole alkylamine derivatives that block histamine H3-receptors.

USPTO Abstract

The present invention provides new method of treatment of Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamine derivatives that constitute antagonists of the H3-receptors of histamine.

Drugs covered by this patent

pitolisant-hydrochloride (PITOLISANT HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1101`	—	pitolisant-hydrochloride
`U-1101`	—	pitolisant-hydrochloride

Patent Metadata

Patent number: US8486947
Jurisdiction: US
Classification: Method of Use
Expires: 2029-09-26
Drug substance claim: No
Drug product claim: No
Assignee: Bioprojet SC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.